New studies highlight major progress in non-small cell lung cancer (NSCLC) treatment, particularly with targeted therapies and antibody-drug conjugates.
The combination of amivantamab and lazertinib achieved a median overall survival of 41 months in treatment-naive patients with atypical EGFR-mutated NSCLC. Pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, showed a 70% response rate and 100% disease control when combined with chemotherapy in advanced NSCLC without actionable mutations.
Next-generation EGFR inhibitors also delivered promising results. Silevertinib produced strong responses in patients with brain metastases, while DZD6008 showed activity against difficult EGFR resistance mutations that emerge after osimertinib treatment.
Meanwhile, sacituzumab tirumotecan combined with pembrolizumab reduced the risk of disease progression or death by 65% compared with pembrolizumab alone in PD-L1–positive advanced NSCLC, significantly outperforming standard immunotherapy.